Les comorbidités influencent-elles le traitement par immunotoxines ?
Oui, les comorbidités peuvent affecter la tolérance et l'efficacité des immunotoxines.
ComorbiditésTolérance au traitementEfficacité thérapeutique
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Immunotoxines : Questions médicales les plus fréquentes",
"headline": "Immunotoxines : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Immunotoxines : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-02-01",
"dateModified": "2025-04-26",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Immunotoxines"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Noxas",
"url": "https://questionsmedicales.fr/mesh/D009676",
"about": {
"@type": "MedicalCondition",
"name": "Noxas",
"code": {
"@type": "MedicalCode",
"code": "D009676",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.888.569"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Immunotoxines",
"alternateName": "Immunotoxins",
"code": {
"@type": "MedicalCode",
"code": "D000922",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Ira Pastan",
"url": "https://questionsmedicales.fr/author/Ira%20Pastan",
"affiliation": {
"@type": "Organization",
"name": "Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, United States."
}
},
{
"@type": "Person",
"name": "Raquel Ibáñez-Pérez",
"url": "https://questionsmedicales.fr/author/Raquel%20Ib%C3%A1%C3%B1ez-P%C3%A9rez",
"affiliation": {
"@type": "Organization",
"name": "Apoptosis, Immunity and Cancer Group, Aragón Health Research Institute (IIS-Aragón), University of Zaragoza, 50009 Zaragoza, Spain."
}
},
{
"@type": "Person",
"name": "Patricia Guerrero-Ochoa",
"url": "https://questionsmedicales.fr/author/Patricia%20Guerrero-Ochoa",
"affiliation": {
"@type": "Organization",
"name": "Apoptosis, Immunity and Cancer Group, Aragón Health Research Institute (IIS-Aragón), University of Zaragoza, 50009 Zaragoza, Spain."
}
},
{
"@type": "Person",
"name": "Alberto Anel",
"url": "https://questionsmedicales.fr/author/Alberto%20Anel",
"affiliation": {
"@type": "Organization",
"name": "Apoptosis, Immunity and Cancer Group, Aragón Health Research Institute (IIS-Aragón), University of Zaragoza, 50009 Zaragoza, Spain."
}
},
{
"@type": "Person",
"name": "Tapan K Bera",
"url": "https://questionsmedicales.fr/author/Tapan%20K%20Bera",
"affiliation": {
"@type": "Organization",
"name": "Laboratory of Molecular Biology, Center for Cancer Research, NCI, NIH, Bethesda, MD 20892, USA."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Incidental finding of intramural splenic heterotopy in the colon mimicking subepithelial neoplasm: a case report.",
"datePublished": "2024-09-19",
"url": "https://questionsmedicales.fr/article/39294715",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1186/s13256-024-04766-y"
}
},
{
"@type": "ScholarlyArticle",
"name": "Difference in the prevalence of advanced colon adenoma between patients with gastric neoplasm and healthy people: A STROBE-compliant study.",
"datePublished": "2022-05-27",
"url": "https://questionsmedicales.fr/article/35623070",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1097/MD.0000000000029308"
}
},
{
"@type": "ScholarlyArticle",
"name": "Microbiome in Colonic Carcinogenesis.",
"datePublished": "2023-06-26",
"url": "https://questionsmedicales.fr/article/37358517",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1002/cphy.c210052"
}
},
{
"@type": "ScholarlyArticle",
"name": "Compound Capecitabine Colon-Targeted Microparticle Prepared by Coaxial Electrospray for Treatment of Colon Tumors.",
"datePublished": "2022-09-03",
"url": "https://questionsmedicales.fr/article/36080457",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3390/molecules27175690"
}
},
{
"@type": "ScholarlyArticle",
"name": "MLH1 Gene Expression in Peripheral Blood in Colon Cancer Patients and Their Association with Colon Cancer.",
"datePublished": "2024-09-27",
"url": "https://questionsmedicales.fr/article/39400169",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3791/66387"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Actions chimiques et utilisations",
"item": "https://questionsmedicales.fr/mesh/D020164"
},
{
"@type": "ListItem",
"position": 3,
"name": "Actions toxiques",
"item": "https://questionsmedicales.fr/mesh/D004786"
},
{
"@type": "ListItem",
"position": 4,
"name": "Noxas",
"item": "https://questionsmedicales.fr/mesh/D009676"
},
{
"@type": "ListItem",
"position": 5,
"name": "Immunotoxines",
"item": "https://questionsmedicales.fr/mesh/D000922"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Immunotoxines - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Immunotoxines",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-17",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Immunotoxines",
"description": "Comment diagnostiquer une maladie ciblée par immunotoxines ?\nQuels tests sont utilisés pour évaluer l'efficacité des immunotoxines ?\nLes immunotoxines sont-elles testées en essais cliniques ?\nQuels biomarqueurs sont associés aux immunotoxines ?\nComment évaluer la toxicité des immunotoxines ?",
"url": "https://questionsmedicales.fr/mesh/D000922?mesh_terms=Colonic+Neoplasms#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Immunotoxines",
"description": "Quels symptômes peuvent indiquer une réaction aux immunotoxines ?\nLes immunotoxines provoquent-elles des effets secondaires ?\nComment reconnaître une allergie aux immunotoxines ?\nLes symptômes varient-ils selon le type d'immunotoxine ?\nQuels signes indiquent une efficacité des immunotoxines ?",
"url": "https://questionsmedicales.fr/mesh/D000922?mesh_terms=Colonic+Neoplasms#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Immunotoxines",
"description": "Peut-on prévenir les effets secondaires des immunotoxines ?\nY a-t-il des mesures préventives avant le traitement ?\nComment minimiser les risques d'allergies aux immunotoxines ?\nLes patients doivent-ils être informés des risques ?\nQuelles sont les recommandations pour les patients sous immunotoxines ?",
"url": "https://questionsmedicales.fr/mesh/D000922?mesh_terms=Colonic+Neoplasms#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Immunotoxines",
"description": "Comment les immunotoxines sont-elles administrées ?\nLes immunotoxines sont-elles combinées avec d'autres traitements ?\nQuel est le mécanisme d'action des immunotoxines ?\nLes immunotoxines sont-elles efficaces contre tous les cancers ?\nQuels sont les protocoles de traitement avec immunotoxines ?",
"url": "https://questionsmedicales.fr/mesh/D000922?mesh_terms=Colonic+Neoplasms#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Immunotoxines",
"description": "Quelles complications peuvent survenir avec les immunotoxines ?\nComment gérer les complications liées aux immunotoxines ?\nLes complications sont-elles prévisibles ?\nLes complications varient-elles selon le patient ?\nQuels signes indiquent une complication grave ?",
"url": "https://questionsmedicales.fr/mesh/D000922?mesh_terms=Colonic+Neoplasms#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Immunotoxines",
"description": "Quels facteurs augmentent le risque d'effets secondaires ?\nLes antécédents familiaux influencent-ils le risque ?\nLe mode de vie affecte-t-il le risque d'effets indésirables ?\nLes interactions médicamenteuses sont-elles un facteur de risque ?\nLes comorbidités influencent-elles le traitement par immunotoxines ?",
"url": "https://questionsmedicales.fr/mesh/D000922?mesh_terms=Colonic+Neoplasms#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une maladie ciblée par immunotoxines ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le diagnostic repose sur des tests d'imagerie, des biopsies et des marqueurs tumoraux."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour évaluer l'efficacité des immunotoxines ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests de réponse tumorale, des analyses sanguines et des examens d'imagerie sont utilisés."
}
},
{
"@type": "Question",
"name": "Les immunotoxines sont-elles testées en essais cliniques ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elles sont souvent évaluées dans des essais cliniques pour leur sécurité et efficacité."
}
},
{
"@type": "Question",
"name": "Quels biomarqueurs sont associés aux immunotoxines ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les biomarqueurs tumoraux spécifiques peuvent indiquer la réponse aux immunotoxines."
}
},
{
"@type": "Question",
"name": "Comment évaluer la toxicité des immunotoxines ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "La toxicité est évaluée par des tests de laboratoire et des suivis cliniques réguliers."
}
},
{
"@type": "Question",
"name": "Quels symptômes peuvent indiquer une réaction aux immunotoxines ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des symptômes comme des nausées, des vomissements ou des réactions cutanées peuvent survenir."
}
},
{
"@type": "Question",
"name": "Les immunotoxines provoquent-elles des effets secondaires ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des effets secondaires comme fatigue, fièvre et douleurs peuvent se manifester."
}
},
{
"@type": "Question",
"name": "Comment reconnaître une allergie aux immunotoxines ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des éruptions cutanées, démangeaisons ou gonflements peuvent signaler une allergie."
}
},
{
"@type": "Question",
"name": "Les symptômes varient-ils selon le type d'immunotoxine ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les symptômes peuvent varier en fonction de la cible et de la toxine utilisée."
}
},
{
"@type": "Question",
"name": "Quels signes indiquent une efficacité des immunotoxines ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une réduction de la taille de la tumeur ou une amélioration des symptômes sont des signes."
}
},
{
"@type": "Question",
"name": "Peut-on prévenir les effets secondaires des immunotoxines ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des médicaments préventifs et un suivi médical peuvent aider à réduire les effets secondaires."
}
},
{
"@type": "Question",
"name": "Y a-t-il des mesures préventives avant le traitement ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des évaluations de santé et des tests allergiques peuvent être effectués avant le traitement."
}
},
{
"@type": "Question",
"name": "Comment minimiser les risques d'allergies aux immunotoxines ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un historique médical complet et des tests cutanés peuvent aider à identifier les risques."
}
},
{
"@type": "Question",
"name": "Les patients doivent-ils être informés des risques ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une information claire sur les risques et bénéfices est essentielle avant le traitement."
}
},
{
"@type": "Question",
"name": "Quelles sont les recommandations pour les patients sous immunotoxines ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les patients doivent suivre les conseils médicaux et signaler tout effet indésirable rapidement."
}
},
{
"@type": "Question",
"name": "Comment les immunotoxines sont-elles administrées ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles sont généralement administrées par voie intraveineuse dans un cadre clinique."
}
},
{
"@type": "Question",
"name": "Les immunotoxines sont-elles combinées avec d'autres traitements ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elles peuvent être combinées avec la chimiothérapie ou la radiothérapie pour plus d'efficacité."
}
},
{
"@type": "Question",
"name": "Quel est le mécanisme d'action des immunotoxines ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles ciblent spécifiquement les cellules malades en délivrant une toxine qui les détruit."
}
},
{
"@type": "Question",
"name": "Les immunotoxines sont-elles efficaces contre tous les cancers ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, leur efficacité dépend du type de cancer et des caractéristiques des cellules tumorales."
}
},
{
"@type": "Question",
"name": "Quels sont les protocoles de traitement avec immunotoxines ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les protocoles varient selon le type de cancer et incluent des cycles de traitement spécifiques."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec les immunotoxines ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des complications comme des infections, des réactions allergiques ou des lésions organiques peuvent survenir."
}
},
{
"@type": "Question",
"name": "Comment gérer les complications liées aux immunotoxines ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "La gestion inclut des soins symptomatiques et parfois l'arrêt temporaire du traitement."
}
},
{
"@type": "Question",
"name": "Les complications sont-elles prévisibles ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines complications peuvent être anticipées, mais d'autres peuvent survenir de manière imprévisible."
}
},
{
"@type": "Question",
"name": "Les complications varient-elles selon le patient ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les complications peuvent varier en fonction de la santé générale et des antécédents médicaux."
}
},
{
"@type": "Question",
"name": "Quels signes indiquent une complication grave ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des signes comme des douleurs thoraciques, des difficultés respiratoires ou des saignements doivent alerter."
}
},
{
"@type": "Question",
"name": "Quels facteurs augmentent le risque d'effets secondaires ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'âge avancé, des antécédents d'allergies et des maladies préexistantes peuvent augmenter le risque."
}
},
{
"@type": "Question",
"name": "Les antécédents familiaux influencent-ils le risque ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des antécédents familiaux de maladies peuvent augmenter le risque de complications."
}
},
{
"@type": "Question",
"name": "Le mode de vie affecte-t-il le risque d'effets indésirables ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un mode de vie sain peut réduire le risque d'effets indésirables liés aux traitements."
}
},
{
"@type": "Question",
"name": "Les interactions médicamenteuses sont-elles un facteur de risque ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certaines interactions médicamenteuses peuvent augmenter le risque d'effets secondaires."
}
},
{
"@type": "Question",
"name": "Les comorbidités influencent-elles le traitement par immunotoxines ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les comorbidités peuvent affecter la tolérance et l'efficacité des immunotoxines."
}
}
]
}
]
}
Engineering Research Center of Cell and Therapeutic Antibody, Ministry of Education, School of Pharmacy, Shanghai Jiao Tong University, 800 Dongchuan Road, Shanghai 200240, People's Republic of China; Jecho Laboratories, Inc., 7320 Executive Way, Frederick MD21704, USA. Electronic address: jianweiz@sjtu.edu.cn.
Applied Microbiology Research Center, Systems Biology and Poisonings Institute, Baqiyatallah University of Medical Sciences, Vanak Sq. Molasadra St., P.O. Box 19395-5487, Tehran, Iran.
Department of Pharmacology, School of Pharmacy, Fujian Provincial Key Laboratory of Natural Medicine Pharmacology, Fujian Medical University, Fuzhou 350122, China.
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
2021-01-21
Department of Pharmacology, School of Pharmacy, Fujian Provincial Key Laboratory of Natural Medicine Pharmacology, Fujian Medical University, Fuzhou 350122, China. Electronic address: jmxie@fjmu.edu.cn.
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
2021-01-21
The aim of this case report is describe an unprecedented case with histological and immunohistochemical diagnosis of splenic heterotopy in the colon using material obtained by endoscopic ultrasound-gu...
Splenic heterotopia is a benign condition characterized by the implantation of splenic tissue in areas distant from its usual anatomical site, such as the peritoneum, omentum, mesentery, liver, pancre...
A 35-year-old white male patient who was healthy, with no history of trauma or splenectomy, but had a family history of colorectal neoplasia underwent colonoscopy for screening. The examination reveal...
This is the first report of a primary intramural colic splenosis case with histological and immunohistochemical diagnosis of splenic heterotopia in the colon, using material obtained by endoscopic ult...
We compared the prevalence of adenoma and cancerous colon polyps in patients undergoing endoscopic removal or gastric surgery for gastric adenoma or gastric cancer and in healthy individuals.The medic...
Microbiomes include bacteria, viruses, fungi, and other microbes. The microbiome modulates numerous aspects of host physiology and is critical in the pathophysiology of diseases, including colon cance...
To improve the antitumor effect of combined capecitabine (CAP) and osimertinib (OSI) therapy and quickly and efficiently reduce tumor volumes for preoperative chemotherapy, we designed a compound CAP ...
MutL homolog 1 (MLH1) is a component of the heterodimeric complex MutLα that detects and fixes base-base mismatches and insertion/deletion loops caused by nucleotide misincorporation. In the absence o...
Schwannomas are nerve sheath tumours that can be found throughout the body along peripheral nerves. Primary schwannomas of the colon are very rare. They are usually benign and their surgical resection...
Despite advances in endoscopic techniques for management of benign colonic neoplasms, a rise in rates of surgical treatment has been reported. We used a nationally representative cohort to characteriz...
All patients undergoing elective partial colectomy for benign or malignant colonic neoplasms were identified using the 2012-2019 National Inpatient Sample. Those presenting with inflammatory bowel dis...
Of 569,280 colectomy procedures included for analysis, 153,435 (27.0%) were performed for benign lesions. The proportion of Benign operations decreased from 28.6% in 2012 to 23.7% in 2019 (P for trend...
The present national study identifies a decrease in colectomy for benign polyps from 2012-2019. Future investigations should identify patients who would most benefit from surgical resection and addres...
A man in his 60s presented to our emergency department with severe peripheral pitting oedema, weight gain, dyspnoea and diarrhoea. Blood tests showed a hypoalbuminaemia of 15 g/L. A suspicion of prote...
To evaluate DNA ploidy and S-phase fraction (SPF) in non-Lynch colonic adenocarcinoma, ulcerative colitis (UC), Crohn disease (CD) which are known as risk factors, and colitis. We correlated ploidy an...
All studied adenocarcinomas have intact mismatch repair genes as proved by immunohistochemistry. All were assessed for ploidy by automated image-based DNA cytometry and histograms were drawn. Immunost...
there is significant difference in DNA ploidy between groups; 77.5% and 17.5% of aneuploid cases are adenocarcinoma and UC. Groups are compared in terms of 2C, 4C, above 4C DNA content and SPF and sig...
Based on significant difference in ploidy between adenocarcinoma and UC and between SPF and ploidy, assessment of ploidy by DNA cytometry for UC and other colitis could therefore predict impending mal...
Colonic malakoplakia is an uncommon granulomatous development of cells resulting from the impaired capacity of the mononuclear cells to eliminate the phagocytosed bacteria, and in rare cases it can al...